Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.6.1.19 (
GABA transaminase
)
808
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The number of cerebellar Purkinje cells is increased by over 40% in young transgenic mice that overexpress a human
Bcl-2
transgene (Hu-Bcl-2). To determine whether the
Bcl-2
-mediated rescue of Purkinje cells persists through life, the numbers of Purkinje cells were estimated in 6-, 12-, 18-, and 24-month-old Hu-
Bcl-2
transgenic mice and age-matched controls. In addition, the expression of four markers for Purkinje cell differentiation, calbindin (CaBP), the 67-kDa isoform of glutamic acid decarboxylase (GAD67),
gamma-aminobutyric acid transaminase
(
GABA-T
), and the NMDA-R1 receptor subtype (NMDA-NR1) was analyzed in 6-month-old Hu-
Bcl-2
transgenics and controls to determine whether overexpression of
Bcl-2
and rescue from naturally occurring cell death affects the normal differentiation of Purkinje cells. The estimates of Purkinje cell numbers showed that the number of Purkinje cells in the Hu-
Bcl-2
transgenics declines after 6 months to approach wild-type values by 18 months. Although the exogenous human BCL-2 is still expressed in Purkinje cells at 24 months, the expression levels of human BCL-2 appear to decline significantly after 6 months, suggesting that survival of the supernumary Purkinje cells depends on the sustained overexpression of
Bcl-2
. All the Purkinje cells in the Hu-
Bcl-2
transgenic mice appeared to express normal levels of the differentiation markers analyzed so there was no evidence for a class of Purkinje cells that do not differentiate normally when rescued from naturally occurring cell death.
...
PMID:Cerebellar Purkinje cell loss in aging Hu-Bcl-2 transgenic mice. 1523 31